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Abstract
Background: A mouse model of metastasis of human gastric cancer is one of the most important tools for
studying the biological mechanisms underlying human gastric cancer metastasis. In this paper, we established a
mouse model of metastatic human gastric cancer in nude mice that has a higher rate of tumor formation and
metastasis than existing models.
Methods: To generate the mouse model of metastatic human gastric cancer, fresh tumor tissues from patients that
have undergone surgery for gastric cancer were subcutaneously implanted in the right and left groins of nude
mice. When the implanted tissue grew to 1 cubic centimeter, the mice were killed, and the tumor tissues were
examined and resected. The tumor tissues were implanted into nude mice and subjected to pathological
examination, immunohistochemical staining, and real-time PCR for cytokeratin 8/18 (CK8/18), E-cadherin, vascular
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). The mice were also analyzed for
metastasis in their peritoneum, abdominal cavity, and internal organs by histopathological examination. Tissues
collected from these organs were examined for pathology.
Results: After ten generations of implantation, all mice developed tumor growth at the implanted position, 94 %
of the mice developed metastasis to the retroperitoneum and viscera. The implanted and metastatic tumor
maintained the same histological features across all generations, and metastasis was observed in the esophagus,
stomach, spleen, liver, kidney, adrenal, intestine, and pancreas. These metastatic tumors revealed no detectable
expression of CK8/18, E-cadherin, VCAM-1, and ICAM-1.
Conclusions: This model will serve as valuable tool for understanding the metastatic process of human gastric
cancer.
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Background
Gastric cancer is the fourth most common malignancy
and the second leading cause of cancer deaths only to
lung cancer in the world [1]. Although the prognosis of
patients with early gastric cancer has been prolonged
distinctly by current methods of diagnosis and treat-
ment, the 5-year survival rate after diagnosis of gastric
cancer patients with all stages is <50 % [2]. Metastasis
accounts in part for the high mortality from gastric
cancer. The proportion of patients with gastric cancer
dying from peritoneum metastasis is approximately 50 %
[3]. Therefore, metastasis has become a focus of many
gastric cancer studies. Metastasis is a very complex
process, involving multiple consecutive steps [4]. Genes
associated with cell adhesion, motility, proliferation, sur-
vival, metabolism, and signal transduction play an im-
portant role in cancer metastasis [5–8]. How these
proteins work collectively to promote metastasis remains
poorly understood.
A mouse model of metastatic gastric cancer is an ex-
tremely valuable tool in understanding the metastatic
process. The first human carcinoma model in nude mice
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was established in 1969 by Rygaard and Povlsen through
hypodermical transplantation of human colon cancer tis-
sue [9]. Although the transplanted tumor retained its
malignant characteristics, it lost its metastatic potential,
and the original structure and behavior of the tumor
changed [10]. A metastatic model of human colon can-
cer was first constructed by Morikawa in 1988 using hu-
man colon cancer cells subserously implanted into
cecum [11]. This model showed orthotopic tumor
growth and liver metastasis. Furukawa further modified
this model in 1993 by surgically stitching human gastric
cancer tissue into the tunica serosa gastria of nude mice
[12]. This model developed tumors robustly and showed
a very high rate of metastasis to the liver. Since disrup-
tion of the adhesion of the tumor tissue alters its bio-
logical and malignant behavior, the mouse models
described retained the integrity of the tumors allowing
for a “patient-like-model” [13, 14]. Hereafter, many
mouse models of metastatic human gastric cancer have
been generated by orthotopic transplantation of gastric
cancer tissue [15–18].
The mouse models of metastatic human gastric cancer
reported so far pose multiple challenges; the orthotic im-
plantation into nude mice required surgery, and the
tumor tissues implanted were derived from human gas-
tric cancer cell line instead of patients. As a result, the
procedure is lengthy and could cause heavy bleeding and
death in mice. Moreover, although the rate of orthotopic
tumor formation is nearly 80–100 %, the rate of metas-
tasis not as high; the liver tumor metastatic rates were at
45–60 % [16, 17] and that with the peritoneum at a
merely 40 % [18]. Thus, establishment of these mouse
models could benefit from improved methods that
would make transplantation easier and result in a more
robust metastasis. In this report, we described a mouse
model of metastatic human stomach cancer that ad-
dresses the issues from previous mouse models. We
established our mouse model of metastatic human stom-
ach cancer through subcutaneous implantation of tumor
tissues derived surgically directly from patients with gas-
tric cancer. Compared to other mouse models described
previously, this mouse model forms tumors at a high
rate and more importantly, shows robust metastasis.
Methods
Ethics statement
All the protocols involving the use of experimental ani-
mals and tumor tissues from patients with gastric cancer
in this study were approved by the Ethics Committee of
Medicine and Science Research Institute of Gansu
Province (laboratory animals science group and clinical
trial group, reference number: P201108150024), the ap-
proved programs included the collection, processing and
implantation of tumor tissues from patients with gastric
cancer , and the resection, storage and examination of
tumor tissues from nude mice. All study participants
provided informed consent to participate in the study.
Animals and clinical tumor tissues
BALB/C nude mice at 4–6 weeks of age and 16–18 g in
weight, both male and female, were provided by Shanghai
Tumor Institute and reared in specific-pathogen-free
(SPF) condition. Tumor tissues were obtained from
patients with gastric cancer who underwent surgery in the
Gansu Tumor Hospital. The fresh tumor tissues were im-
planted immediately after resection. Clinical data of the
patients are listed in Table 1.
Subcutaneous implantation of fresh tumor tissues into
nude mice
The fresh tumor tissues resected from patients with gas-
tric cancer were cut to 1 cubic millimeter pieces which
were diluted with DMEM medium, and then subcutane-
ously implanted into the right and left armpits and
groins of nude mice with 16-gague needle under aseptic
condition. Each sample was implanted to four mice, 5–6
pieces (0.8 mL) per mouse. The nude mice were subse-
quently reared in SPF condition, and the tumor growth
on nude mice was examined daily. Once the tumor on
the nude mice has grown to 1 cubic centimeter, the
mouse was killed by cervical dislocation and the tumor
tissues were examined and resected in aseptic condition.
The tumor tissue from each mice was separated into
three parts - one was used for another round of implant-
ation into nude mice, the other was fixed in 10 %
formaldehyde for pathological examination and immu-
nohistochemical (IHC) staining for CK8/18, E-cadherin,
Table 1 Clinical data
Samplea Histopathologic classification Clinical stages Rate of lymph node metastasis
1st poorly differentiated adenocarcinoma PT4aN3a M0 IIIc 7/30
2nd moderately differentiated adenocarcinoma PT4aN0M0 IIb 0/12
3rd ulcerative type moderately differentiated adenocarcinoma PT4aN0M0 IIb 0/30
4th poorly differentiated adenocarcinoma PT4aN3a M0 IIIc 16/17
a1st and 4th gastric cancer tissue were poorly differentiated adenocarcinoma and have lymph node metastasis. 2nd and 3rd were moderately differentiated
adenocarcinoma and have no lymph node metastasis
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VCAM-1, and ICAM-1, the third was stored in liquid
nitrogen and in −80 °C for real-time PCR analysis of
CK8/18, E-cadherin, VCAM-1, and ICAM-1. The mice
were dissected and examined for tumor metastasis in
their peritoneum, abdominal cavity, liver, spleen, stom-
ach, intestines, kidneys, lung, and brain. Collected tis-
sues were fixed in 10 % formaldehyde for pathological
examination.
Establishment and characterization of mouse model of
metastatic human gastric cancer
The excised tumor tissue was subcutaneously implanted
to the right and left groins of 5 nude mice under aseptic
condition using 5–6 pieces (0.8 mL) per mouse. The cut-
ting and diluting of tumor tissue, growth examination
and resection of the tumor in the nude mice, storage
and examination of the implanted tumor tissues, meta-
static tumor tissues, and mouse bodies were processed
as described above. Implanted tumor tissues were pas-
saged for ten generations.
Examining effect of the site of implantation on the rate of
metastasis
As described, the implanted human gastric cancer tissue
from nude mice was subcutaneously implanted to three
groups of nude mice at different sites under aseptic con-
dition. An average of 5–6 pieces were implanted into
mice, with one group receiving the tissues at the right
and left groins, the other group at the right and left arm-
pits, and the third at two sites in the back. As mentioned
above, growth examination and resection of the tumor
in the nude mice were processed. Further analyses in-
cluded examination of tumor growth at different sites
and metastasis in the peritoneum and abdominal cavity.
Implantation and metastasis of previously frozen and
passaged human gastric cancer tissue in nude mice
The implanted human gastric cancer tissues passaged
from fourth and eighth generation by implantation into
nude mice were stored in liquid nitrogen and subcutane-
ously implanted into nude mice at the right and left
groins as described above. Further analyses included
examination of tumor growth at different sites and me-
tastasis in the peritoneum and abdominal cavity.
Pathological examination of the implanted and metastatic
human gastric tissues from nude mice
The implanted and metastatic human gastric cancer tis-
sues from nude mice were fixed in 10 % formaldehyde,
embedded in paraffin, cut into sections, stained in
Hematoxylin-eosin staining (HE). The slides were evalu-
ated using an Olympus BX50 light microscope, and
image acquisition was performed by Mias pathological
workstation 4.0 system.
IHC staining
The expression levels of E-cadherin, VCAM-1, ICAM-1,
and CK8/18 were examined by immunohistochemistry
in the implanted and metastatic tumor tissues from
nude mice and in the surgical specimens used for im-
plantation. Sections used for staining were obtained
from the surgical specimens, the implanted and meta-
static tumor tissues, and the tissues that contain meta-
static tumors. Reagents used for staining were SP-9000
Histostain™-plus Kits, 3-3′-Diaminobenzidine tetrahy-
drochloride (DAB) Kits, primary mouse monoclonal
antibodies against E-cadherin (1:200 dilution), ICAM-1
(1:500 dilution), and primary rabbit polyclonal antibody
against VCAM-1 (1:500 dilution) (Beijing Zhongshan
Golden Bridge Biotechnology Co Ltd., Beijing, China).
The IHC staining slides were independently assessed by
two pathologists, and any difference in the decision out-
come was resolved by consensus. Staining intensity was
assessed as negative, weak, moderate, or strong. The
light microscope and image acquisition software were
the same as above.
Total RNA extraction and real-time PCR
Total RNA was extracted by Trizol (Sheng gong Bio-
technology, Shanghai, China) from the implanted and
metastatic tumor tissues that grew in nude mice and
from the surgical specimens used for implantation, fol-
lowing manufacturer’s instructions. The cDNA was
synthesized by reverse transcriptase (Sheng gong Bio-
technology), according to the manufacturer’s recommen-
dations. The SYBR premix Ex TaqTM (TaKaRa
Biotechnology, Dalian, China) was used for the real-time
PCR. The 20-μl reaction contained 10 μl SYBR premix
Ex TaqTM, 1 μl DNA template, 0.4 μl each primer, and
8.2 μl dH20. The PCR cycling condition was: 37 °C for
5 min, 95 °C for 30 s, and 40 cycles of 95 °C for 5 s to
60 °C for 30 s. The β-actin mRNA was used as internal
control, and the reaction mix without the template DNA
was used as negative control. All of the samples were
measured 3 times independently, and the quantitative
PCR data were analyzed using the comparative CT
method. Briefly, the difference in cycle threshold, ΔCT,
was determined as the difference between the tested
gene and human β-actin. We then obtained ΔΔCT by
finding the difference between the two groups. The fold
change was calculated as 2 -ΔΔCT. The primers are listed
in Table 2.
Results
Tumor formation and metastasis
Among the four mice implanted with the 1st surgical
specimens, only one developed tumor at the site of im-
plantation by 76 days (Fig. 1a). Twenty-five days later,
the mouse was killed by cervical dislocation and
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analyzed for tumors. Tumor tissue at an average of 1
cubic centimeter in size, displayed an intact envelope
and hard texture (Fig. 1b). Metastasis in the retroperito-
neum was found by visual inspection (Fig. 1c). No me-
tastasis was detected in its peritoneum, abdominal
cavity, liver, spleen, stomach, intestines, kidneys, lung,
and brain.
Pathological analysis revealed that the implanted and
metastatic tumor tissues consisted of poorly differenti-
ated carcinoma cells, and only a little of mesenchyma
and blood vessel. These tissues appear diffused, lacked
structure, and resemble glandular lumen. Moreover, the
cells displayed dark-stained nuclei, scant cytoplasm, and
misproportioned nuclei and cytoplasm (Fig. 1d, e, f ).
Similar results were obtained in a parallel study involv-
ing implantation of the tumor tissue into 4 mice; only
one mouse developed tumor (average size: 1.5 cubic
centimeter) 26 days after implantation. No metastasis
was observed in its peritoneum, abdominal cavity, liver,
spleen, stomach, intestines, kidneys, lung, and brain.
The other mice implanted with the 2nd and 4th surgical
specimens showed no tumor growth.
Stability of the implanted tumor following passage into
multiple generations
The tumor that developed from the 1st surgical speci-
men was passaged for ten generations. The rate of tumor
growth was 100 % and that of metastasis in retroperito-
neum and viscera was 80–100 % (average 94 %), regard-
less whether the primary tissue was used fresh or frozen
(Table 3). The viscera metastasis was observed in the
lymph nodes around esophagus, below gastric mucosa,
tunica serosa gastria, spleen, liver portal area, central ve-
nae and sinus hepaticus, liver parenchyma, liver capsule,
renal hilum, kidney parenchyma, adrenal gland, intestine
Table 2 Primers used in the real-time PCR









Fig. 1 Metastatic tumor growth from the implanted gastric cancer tissue obtained surgically (X 400). a, b: Implanted cancer tissue grew to ~1
cubic centimeter and displayed an intact envelope and hard texture; c: Tumor metastasized into the mouse retroperitoneum; d, e: The implanted
tissue and metastatic tumors consisted of poorly differentiated carcinoma cells and a few mesenchyma cells and blood vessels, with some
resemblance to glandular cavity. The cancer cells showed dark-stained nuclei and scant cytoplasm and lacked the normal proportion between
nucleus and cytoplasm; f: Implanted tumor showing tissue infiltration
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serosa, pancreas, and spermaduct (Fig. 2). The gener-
ation time is 16 days.
The rate of metastasis of the tumor implanted into
different positions
Implantation into different positions affected the rate of
metastasis but not the rate of tumor growth. Implant-
ation into the groin resulted in 94 % retroperitoneum
and viscera metastasis; implantation into the back re-
sulted in 30 % retroperitoneum metastasis and 10 % vis-
cera metastasis; implantation into armpits resulted in no
retroperitoneum metastasis and 20 % viscera metastasis.
The generation time was: 16 days for tumors implanted
in the groins, 20 days for those implanted in the back,
and 14 days for those implanted in the armpits (Table 3).
The metastatic viscera included liver (50 %), kidney
(44 %), intestine (28 %), esophagus (12 %), pancreas
(12 %), stomach (6 %), spleen (6 %), and spermaduct
(6 %) (Table 4).
Characterization of the implanted and metastatic tumor
The IHC and real-time PCR results revealed that ICAM-
1, VCAM-1, and CK8/18, but not E-cadherin, were pre-
dominantly expressed at surgery and in the implanted
tumor of primary and first generation (Fig. 3). As shown
in Table 5, the primary and first generation of the tumor
showed positive staining for VCAM-1 and CK8/18, but
the subsequent generations showed weak staining for
these proteins: VCAM-1 staining was scored as moder-
ately positive (++) in the primary, weak signal (+) in the
first generation, and CK8/18 staining was scored as weak
signal (+) in the first generation. Tumors at all stages
showed negative staining for E-cadherin, whereas meta-
static tumor at all generations showed negative staining
for E-cadherin, ICAM-1, VCAM-1, and CK8/18. As for
the transcripts, we detected VCAM-1 mRNA in the pri-
mary and first generation implanted tumor but not at
the metastatic stage. E-cadherin and ICAM-1 transcripts
were not detected in all generations of implanted and
metastatic tumors.
Discussion
Cancer is characterized by proliferation, invasion, and
metastasis. More than 90 % of mortality from cancer is
due to metastasis thereby prompting intense research
[19]. Metastasis is a complicated and poorly understood
process involving proteins with functions in cell adhe-
sion, ECM degradation, and motility [19–21]. Numerous
studies on gastric cancer metastasis have been reported
[22–26]. However, most of these studies were conducted
in vitro, failing to mimic the metastatic process that oc-
curs in vivo. This suggests a need for an animal model
of cancer metastasis that has a robust and consistent
phenotype. In the present study, a model of metastatic
Table 3 Stability and rate of metastasis of tumors implanted at different positionsa
Variable No Growth in implanted position (%) Metastasis retroperitoneum (%) Viscera (%) Generation time (days)
Passage number
1st 5 100 (5/5) 100 (5/5) 80 (4/5) 20
2nd 5 100 (5/5) 80 (4/5) 100 (5/5) 14
3rd 5 100 (5/5) 100 (5/5) 80 (4/5) 14
4th 5 100 (5/5) 80 (4/5) 100 (5/5) 15
5th 5 100 (5/5) 100 (5/5) 80 (4/5) 14
6th 5 100 (5/5) 80 (4/5) 100 (5/5) 13
7th 5 100 (5/5) 100 (5/5) 100 (5/5) 17
8th 5 100 (5/5) 100 (5/5) 100 (5/5) 18
9th 5 100 (5/5) 100 (5/5) 100 (5/5) 17
10th 5 100 (5/5) 100 (5/5) 100 (5/5) 18
Stored in liquid nitrogen
4th 5 100 (5/5) 100 (5/5) 100 (5/5) 17
8th 5 100 (5/5) 100 (5/5) 100 (5/5) 18
Implantation in different position
Groins 50 100 (50/50) 94 (47/50) 94 (47/50) 16
Back 10 100 (10/10) 30 (3/10) 10 (1/10) 20
Armpits 10 100 (10/10) 0 (0/10) 30 (3/10) 14
a After ten generations of implantation, all mice developed tumor growth at the implanted position, and 94 % of mice developed metastasis to the
retroperitoneum and viscera, regardless whether the tumor source was fresh or frozen. The average time of bearing tumor is 16 days. The groin of mice is best
Implantation position, resulting in 94 % retroperitoneum and viscera metastasis
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human gastric cancer was established by hypodermic in-
oculation in nude mice with cancer tissues obtained sur-
gically from patients with gastric cancer. All mice
developed tumor growth at the implanted position and
retroperitoneum metastasis, and 94 % of mice developed
metastasis to the viscera, regardless whether the tumor
source was fresh or frozen. The implanted and meta-
static tumor maintained the same features across all
generations, and the viscera metastasis was observed in
lymph nodes around the esophagus, below the gastric
mucosa, tunica serosa gastria, spleen, liver portal area,
central venae and sinus hepaticus, liver parenchyma,
liver capsule, renal hilum, kidney parenchyma, adrenal
gland, intestine serosa, and pancreas. Metastasis was ro-
bust in this mouse model. The retroperitoneum metasta-
sis possibly resulted from the dissociation of tumor cells
Fig. 2 Pathological examination of the tumor that metastasized to the viscera (X 100). Micro-metastasis was observed in the lymph nodes around
the esophagus (a), below the gastric mucosa (b), and in other areas such as tunica serosa gastria (c), parenchyma under hepatic capsule (d), liver
portal area (e), sinus hepaticus (f), spleen (g), venae centrals hepatic (h), pancreas (i), renal hilum (j), renal parenchyma (k), adrenal gland (l),
intestine serosa (m), spermaduct (n), and lung (o)







Intestine (%) Esophagus (%) Pancreas (%) Stomach (%) Spleen (%) Spermaduct
(%)
Groins 50 94 (47/50) 50 (25/50) 44 (22/50) 28 (14/50) 12 (6/50) 12 (6/50) 6 (3/50) 6 (3/50) 6 (3/50)
Back 10 10 (1/10) 0 0 0 0 0 10 (1/10) 10 (1/10) 0
Armpits 10 30 (3/10) 20 (2/10) 0 0 10 (1/10) 0 0 0 0
a Liver and kidney were the viscera with highest rate of metastasis (44–50 %), and the stomach, spleen and spermaduct were the lowest (6 %)
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Fig. 3 IHC analysis of the expression of E-cadherin, VCAM-1, ICAM-1 and CK8/18 (X 200). CK8/18 expression was detected in the surgical specimen
used for implantation (a) and in the primary implanted tumor tissues (b), but not in the F1 generation implanted tumor tissues (c), VCAM-1 was
expressed in the surgical specimen (d), and in the primary implanted tumor tissues (e), but not in the F2 generation implanted tumor tissues (f).
E-cadherin expression was not detectable in the surgical specimen (g) and in the primary implanted tumor tissues (h). ICAM-1 was expressed in
the surgical specimen (i), but not in the primary implanted tumor tissues (j)
Table 5 Expression of E-cadherin, ICAM-1, VCAM-1 and CK8/18 in the tumors at surgery, upon implantation and during metastasis
Variable No Protein expressiona mRNA expressiona
E-cadherin ICAM-1 VCAM-1 CK8/18 E-cadherin ICAM-1 VCAM-1
surgical specimen 1 - +++ +++ +++
Primary 1
Implanted tumor - - ++ + 0 0 0.0927
Metastatic tumor - - - - 0 0 0
1st 5
Implanted tumor − (0/5) − (0/5) + (5/5) − (0/5) 0 0 0.1997
Metastatic tumor − (0/5) − (0/5) − (5/5) − (0/5) 0 0 0
2nd ~ 10th 45
Implanted tumor − (0/45) − (0/45) − (0/45) − (0/45) 0 0 0
Metastatic tumor − (0/42) − (0/42) − (0/42) − (0/42) 0 0 0
aMolecular analysis of the implanted and metastatic tumors revealed no detectable expression of CK8/18, E-cadherin, VCAM-1 and ICAM-1, except positive staining
for VCAM-1 in the implanted tumor tissues of the first generation
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from the implanted tumor, introduction into the inguinal
glands, and transport to the retroperitoneum. This may
account for the tumor metastasizing into liver portal
area, central venae, and sinus hepaticus, as well as into
tunica serosa gastria, renal hilum, adrenal gland, and in-
testine serosa. Metastasis could also have occurred
through the lymph nodes; tumors were observed in the
lymph nodes around esophagus, below gastric mucosa,
spleen, pancreas, and kidney parenchyma.
The occurrence of metastasis appears to be dependent
on the site of implantation subcutaneously: implantation
into the groin resulted in 100 % retroperitoneal metasta-
sis and 94 % viscera metastasis; implantation into the
back resulted in 30 % retroperitoneum metastasis, and
10 % viscera metastasis; implantation into armpits re-
sulted in no retroperitoneum metastasis and 20 % vis-
cera metastasis. This observation is consistent with
metastasis associated with tumor growth microenviron-
ment including blood vessel and lymph distribution. In-
deed, the mouse groin has more blood vessels and
lymph networks that flow into abdominal cavity and vis-
cera than the back. Although the armpits have rich
blood vessels and lymphatic networks, the direction of
the vena is anterograde, and most of lymph connect with
lung, trachea and pleura, locations where gastric cancer
seldom gets translocated. Therefore, the simple method
of subcutaneous implantation of cancer cells into the
groins of nude mice efficiently results in a model of
metastatic human gastric cancer. This model has a
higher viscera metastasis rate than that reported in the
literature [13–18] and could easily be applied to other
types of human cancer.
Tumor invasion with subsequent metastases is the
major cause of morbidity and mortality in patients with
cancer. Cancer metastasis is a complex process in which
tumor cells separate from the primary tumor mass, mi-
grate through the vascular system, extravasate into other
tissues and grow into new tumors [27–30]. Among these
diverse processes, an alteration in the adhesive proper-
ties of the primary tumor cells is a critical factor for
tumor progression [28]. It has been revealed that cell ad-
hesion is responsible for tumor progression, involving
molecules that play a role in cell-cell adhesion and cell-
matrix adhesion [31–34]. Cell adhesion plays an import-
ant role in the two different stages of the tumor
metastatic process - the detachment from the primary
tumor and its adhesion to the circulatory system [27].
Therefore, cell adhesion molecules play a critical role in
the invasion and metastasis of a variety of human
tumors.
E-cadherin plays an important role in cell-cell adhe-
sion in epithelial tissues [35]. Besides its role in normal
cells, this cell adhesion molecule can play a major role
in malignant cell transformation, tumor development,
and progression. The loss of tumor tissue integrity can
lead to local invasion [36]. Therefore, loss of function of
E-cadherin in tumor tissues correlates with invasiveness
and metastasis of tumors [37]. Studies have shown that
aberrant E-cadherin expression is associated with the ac-
quisition of invasiveness and more advanced tumor stage
for gastric cancer [38–40].
ICAM-1 and VCAM-1 are very important cell adhesion
molecules belonging to the immunoglobulin super family.
The ICAM-1 functions in cell-cell and ECM adhesion, in-
cluding physiological polymorphonuclear (PMN) tight
adhesion and trans endothelial migration via the leukocyte
integrins lymphocyte functionassociated antigen-1 (LFA-
1) (CD11a/CD18) and macrophage-1 antigen (MAC-1)
(CD11b/CD18) [41]. The VCAM-I mediates cellular adhe-
sion via integrin [42]. ICAM-1 plays an important role in
cell-cell and cell-ECM interactions, especially tumor inva-
sion and cytotoxicity of lymphocytes. Studies have shown
that the positive expression rate of ICAM-1 was related
with lymph node metastasis and depth of tumor inva-
sion, and the VCAM-1 expression positive gastric can-
cers were more invasive and were associated with more
lymph node metastases than VCAM-1 expression nega-
tive ones [43–45]. Cytokeratin appear on all epithelial
cells, some non-epithelial cells, and most tumor cells.
The cytokeratins, belonging to the intermediate fila-
ment (IF) protein family, are primary components of
horn cells and maintains the organization of epithelial
tissues. Studies have found that the cytokeratins are
very highly conserved and important for tissue differen-
tiation. At present, more than 20 different cytokeratins
have been identified [46], of which CK 8, 18, and 19 are
the most abundant in simple epithelial cells. In the
present study, the IHC and RT-PCR results revealed
that the expression of E-cadherin is negative, and that
of ICAM-1, VCAM-1, and CK8/18 are positive in the
surgical specimen used for implantation, consistent
with past studies [38, 40, 43, 45]. Interestingly, E-
cadherin, ICAM-1, VCAM-1 and CK8/18 are not
expressed in the implanted and metastatic tumor tis-
sues of nude mice, suggesting that the molecular and
biological characteristics of the implanted and meta-
static tumors are different from the original tissue ob-
tained surgically. These differential characteristics may
provide insights into the metastatic process.
Conclusions
Tumor metastasis is a complicated multi-step process.
Although numerous genes and factors have been as-
sociated with tumor metastasis, the exact molecular
mechanisms underlying this process remains poorly
understood. In present study, we have established a
mouse model of metastatic human gastric cancer with
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a robust metastatic phenotype, which will be valuable
in understanding the molecular mechanisms under-
lying this process.
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